ConductScience.org, home

Paper9720548

Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability?

Michel MC and 5 others. J Urol, 1998. Cited by 84 papers, by iCite.

Cite this record

ConductScience Library. Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability? Papers, record 9720548. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9720548

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability?
PubMed
Journal
J Urol
PubMed
Year
1998
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
84
iCite
Relative citation ratio, by iCite
3.57
iCite
Revised in PubMed
2023-03-02
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Michel MCM C
2Mehlburger LL
3Bressel HUH U
4Schumacher HH
5Schäfers RFR F
6Goepel MM

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Adrenergic alpha-AntagonistsMajor topic
HypertensionMajor topic
Prostatic HyperplasiaMajor topic
SulfonamidesMajor topic
Drug Tolerance
Humans
Male
Middle Aged
Tamsulosin

Source PubMed

Download CSV of topics

Cited by27

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 84 citations.

PMIDTitleJournalYearIn PapersSource
40338280Characteristics of men using non-prescription medicines to treat their lower urinary tract symptoms.World J Urol2025https://conductscience.org/library/papers/40338280PubMed
37289405
A systematic review and meta-analysis of efficacy and safety comparing greenlight laser vaporization with transurethral resection of the prostate for benign prostatic hyperplasia with prostate volume less than 80 ml.
Lasers Med Sci2023https://conductscience.org/library/papers/37289405PubMed
37063295Association of diabetes, hypertension, and their combination with basal symptoms and treatment responses in overactive bladder patients.Front Pharmacol2023https://conductscience.org/library/papers/37063295PubMed
34729233The impact of preoperative lower urinary tract symptoms medication on the functional performance of holmium laser enucleation of the prostate.Cent European J Urol2021https://conductscience.org/library/papers/34729233PubMed
33941632Aquablation versus holmium laser enucleation of the prostate in the treatment of benign prostatic hyperplasia in medium-to-large-sized prostates (ATHLETE): protocol of a prospective randomised trial.BMJ Open2021https://conductscience.org/library/papers/33941632PubMed
32880664[Management of geriatric patients with benign prostatic hyperplasia].Urologe A2020https://conductscience.org/library/papers/32880664PubMed
32581791Factors Associated With Nocturia-Related Quality of Life in Men With Lower Urinary Tract Symptoms and Treated With Tamsulosin Oral Controlled Absorption System in a Non-Interventional Study.Front Pharmacol2020https://conductscience.org/library/papers/32581791PubMed
32104330Preparation and stability investigation of tamsulosin hydrochloride sustained release pellets containing acrylic resin polymers with two different techniques.Asian J Pharm Sci2017https://conductscience.org/library/papers/32104330PubMed
29492398Prostatic artery embolization versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia: protocol for a non-inferiority clinical trial.Res Rep Urol2018https://conductscience.org/library/papers/29492398PubMed
25903582Is absorption of irrigation fluid a problem in Thulium laser vaporization of the prostate? A prospective investigation using the expired breath ethanol test.BMC Urol2015https://conductscience.org/library/papers/25903582PubMed
25834406Solifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia.Drug Des Devel Ther2015https://conductscience.org/library/papers/25834406PubMed
25425136Prostatic artery embolization versus conventional TUR-P in the treatment of benign prostatic hyperplasia: protocol for a prospective randomized non-inferiority trial.BMC Urol2014https://conductscience.org/library/papers/25425136PubMed
23370938Embolisation of prostatic arteries as treatment of moderate to severe lower urinary symptoms (LUTS) secondary to benign hyperplasia: results of short- and mid-term follow-up.Eur Radiol2013https://conductscience.org/library/papers/23370938PubMed
21745239Tamsulosin shows a higher unbound drug fraction in human prostate than in plasma: a basis for uroselectivity?Br J Clin Pharmacol2011https://conductscience.org/library/papers/21745239PubMed
21496064Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin.Br J Clin Pharmacol2011https://conductscience.org/library/papers/21496064PubMed
20170206Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations.Clin Pharmacokinet2010https://conductscience.org/library/papers/20170206PubMed
19570487Diabetes and benign prostatic hyperplasia: emerging clinical connections.Curr Urol Rep2009https://conductscience.org/library/papers/19570487PubMed
17953457Pharmacological management of renal colic in the older patient.Drugs Aging2007https://conductscience.org/library/papers/17953457PubMed
17906864Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia.World J Urol2007https://conductscience.org/library/papers/17906864PubMed
16986051A Comparison of Varying alpha-Blockers and Other Pharmacotherapy Options for Lower Urinary Tract Symptoms.Rev Urol2005https://conductscience.org/library/papers/16986051PubMed

See all 27 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/9720548

GET https://conductscience.org/api/papers/v1/9720548/cited_by?page=2